Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salacinol is a naturally occurring sulfonium-ion thiosugar compound isolated from the roots and stems of Salacia species (notably Salacia reticulata and Salacia oblonga), plants used in traditional medicine. It is a potent inhibitor of intestinal alpha-glucosidases—enzymes responsible for breaking down complex carbohydrates into glucose in the gut. By inhibiting these enzymes (including maltase and sucrase), salacinol delays carbohydrate digestion and absorption after meals (postprandial), resulting in reduced blood glucose spikes. Its mechanism is similar to that of acarbose but with higher potency in some studies. The primary therapeutic interest for salacinol lies in managing type 2 diabetes by controlling postprandial hyperglycemia; it has also been explored as a lead compound for new antidiabetic drugs and functional foods targeting metabolic disorders[7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salacinol.